Recherche
-
Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study
(EP-Europace. vol. 22, n° 2, pp. 205-215, 2020)Article de revue -
Six-year survival study after myocardial infarction: The EOLE prospective cohort study. Long-term survival after MI
(Thérapie. vol. 74, n° 4, pp. 459-468, 2019-09)Article de revue -
Treatment resistant depression incidence and prevalence using the French nationwide claims database
(Pharmacoepidemiology and Drug Safety. vol. 30, n° 2, pp. 169–177, 2021-02)Article de revue -
Benefit-risk of rivaroxaban 20 or 15mg compared to vitamin-K antagonists in patients with non-valvular atrial fibrillation: a cohort study in the French nationwide claims database
(European Heart Journal. vol. 39, pp. 1014-1014, 2018-08)Article de revue -
Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample
(Drug Safety. vol. 41, n° 11, pp. 1049-1058, 2018-11)Article de revue -
Patterns of quadruple therapy use including bismuth for Helicobacter pylori eradication: A cohort study in the French national claims database
(Thérapie. vol. 76, n° 5, pp. 435-440, 2021-09)Article de revue -
Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS
(Am J Cardiovasc Drugs. vol. 20, n° 1, pp. 81-103, 2020)Article de revue -
Does Ibuprofen Worsen COVID-19?
(Drug Safety. vol. 43, n° 7, pp. 611-614, 2020)Article de revue -
Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database
(Atherosclerosis. vol. 281, pp. 98-106, 2019)Article de revue -
Pharmacovigilance - The next chapter
(Thérapie. vol. 74, n° 6, pp. 557-567, 2019-12)Article de revue